Crinetics Pharmaceuticals

Yahoo Finance • 6 days ago

Interesting CRNX Put And Call Options For November 21st

Investors in Crinetics Pharmaceuticals Inc (Symbol: CRNX) saw new options begin trading this week, for the November 21st expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the CRNX options chain for the n... Full story

Yahoo Finance • 15 days ago

Crinetics Pharmaceuticals Announces September 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SAN DIEGO, Sept. 10, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that on September 10, 2025, the Compensation Committee of the Board of Directors granted non-qualified stock option awards to pu... Full story

Yahoo Finance • last month

Crinetics Receives FDA Orphan Drug Designation for Atumelnant in the Treatment of Congenital Adrenal Hyperplasia (CAH)

SAN DIEGO, Aug. 21, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that the U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation (ODD) for atumelnant, a novel, once-daily oral a... Full story

Yahoo Finance • last month

Tuesday's pre-market session: top gainers and losers

Before the US market kicks off on Tuesday, let's examine the pre-market session and unveil the notable performers among the top gainers and losers. [premarket] PRE-MARKET GAINERS TICKER CHANGE COMMENT LASE [https://www.chartm... Full story

Yahoo Finance • last month

Crinetics Pharmaceuticals Announces August 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SAN DIEGO, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that on August 10, 2025, the Compensation Committee of the Board of Directors granted non-qualified stock option awards to purcha... Full story

Yahoo Finance • last month

Crinetics stock price target lowered to $86 by Citizens JMP on launch outlook

Investing.com - Citizens JMP has lowered its price target on Crinetics (NASDAQ:CRNX) to $86.00 from $90.00 while maintaining a Market Outperform rating, citing expectations for a modest initial launch of the company’s acromegaly treatment.... Full story

Yahoo Finance • 2 months ago

Crinetics Pharmaceuticals (NASDAQ:CRNX) Is In A Good Position To Deliver On Growth Plans

Just because a business does not make any money, does not mean that the stock will go down. For example, although Amazon.com made losses for many years after listing, if you had bought and held the shares since 1999, you would have made a... Full story

Yahoo Finance • 2 months ago

Crinetics Pharmaceuticals GAAP EPS of -$1.23 misses by $0.13, revenue of $1M beats by $0.51M

* Crinetics Pharmaceuticals press release [https://seekingalpha.com/pr/20194062-crinetics-pharmaceuticals-reports-second-quarter-2025-financial-results-and-provides-business] (NASDAQ:CRNX [https://seekingalpha.com/symbol/CRNX]): Q2 GAAP... Full story

Yahoo Finance • 2 months ago

Crinetics' 48% decline validates InvestingPro's October 2024 overvalued call

In October 2024, Investing.com’s Fair Value model identified Crinetics Pharmaceuticals (NASDAQ:CRNX) as significantly overvalued, demonstrating the power of sophisticated valuation analysis in protecting investor capital. The subsequent ma... Full story

Yahoo Finance • 2 months ago

H.C. Wainwright reiterates Buy rating on Crinetics stock at $81 price target

Investing.com - H.C. Wainwright has reiterated its Buy rating and $81.00 price target on Crinetics (NASDAQ:CRNX) following the ENDO 2025 conference. The target represents significant upside from the current price of $31.11, with analyst ta... Full story

Yahoo Finance • 2 months ago

Crinetics Pharmaceuticals' SWOT analysis: promising pipeline drives stock outlook

Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX), a biopharmaceutical company specializing in oral therapies for endocrine diseases, is garnering attention from investors and analysts alike. With a market capitalization of $3.09 billion, Inve... Full story

Yahoo Finance • 2 months ago

Crinetics stock maintains Buy rating at Jones Trading on positive ENDO'25 data

Investing.com - Jones Trading has reiterated a Buy rating and $71.00 price target on Crinetics (NASDAQ:CRNX), currently trading at $32.80, following the company’s presentations at ENDO’25. According to InvestingPro data, analysts’ targets... Full story

Yahoo Finance • 2 months ago

CRNX March 2026 Options Begin Trading

Investors in Crinetics Pharmaceuticals Inc (Symbol: CRNX) saw new options become available today, for the March 2026 expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with... Full story

Yahoo Finance • 2 months ago

Crinetics to Present New Long-Term Data Demonstrating Durable Control of Once-Daily, Oral PALSONIFY™ (Paltusotine) in Acromegaly at ENDO 2025

Data show that PALSONIFY was well tolerated and IGF-1 levels remained stably controlled during long-term open label extensions of PATHFNDR-1 and PATHFNDR-2 studies Additional PALSONIFY presentations demonstrate reductions in patient-repor... Full story

Yahoo Finance • 2 months ago

Crinetics Pharmaceuticals to Report Second Quarter 2025 Financial Results on August 7, 2025

SAN DIEGO, July 11, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that it will report second quarter 2025 financial results on Thursday, August 7, 2025 after the market closes. Company management... Full story

Yahoo Finance • 3 months ago

Crinetics Pharmaceuticals Announces July 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SAN DIEGO, July 10, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that on July 10, 2025, the Compensation Committee of the Board of Directors granted non-qualified stock option awards to purchase... Full story

Yahoo Finance • 3 months ago

Goldman Sachs initiates coverage on Crinetics stock with Neutral rating

Investing.com - Goldman Sachs initiated coverage on Crinetics Pharmaceuticals (NASDAQ:CRNX) with a Neutral rating and a $36.00 price target on Thursday. The biotech company, currently valued at $3.03 billion, has shown strong momentum with... Full story

Yahoo Finance • 3 months ago

Should You Hold Crinetics Pharmaceuticals (CRNX)?

PGIM Jennison Health Sciences Fund released its first quarter 2025 investor letter. A copy of the letter can be downloaded here. The S&P 1500 Health Care Index returned 5.5% in the first quarter, outperforming the S&P 500’s -4.3% return. B... Full story

Yahoo Finance • 3 months ago

Crinetics Pharmaceuticals' SWOT analysis: stock poised for growth in endocrine treatments

Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX), a $2.79 billion market cap biopharmaceutical company specializing in treatments for rare endocrine diseases and endocrine-related tumors, is positioning itself as a potential leader in the fie... Full story

Yahoo Finance • 3 months ago

Crinetics stock rating reiterated at Market Outperform by JMP ahead of key data

Investing.com - JMP Securities has reiterated its Market Outperform rating and $90.00 price target on Crinetics Pharmaceuticals (NASDAQ:CRNX), currently trading at $28.43, ahead of upcoming Phase 2 data presentation for its congenital adre... Full story